PEBP4 gene expression in lung squamous cell carcinoma: A meta-analysis-based study of the molecular pathways involved.

PEBP4 gene expression in lung squamous cell carcinoma: A meta-analysis-based study of the molecular pathways involved. Oncol Lett. 2020 Apr;19(4):2825-2831 Authors: Yu G, Zhong N, Huang B, Mi Y Abstract Previous studies have suggested increased activity of phosphatidylethanolamine binding protein 4 (PEBP4) may be associated with the prognosis of non-small cell lung cancer. However, to the best of our knowledge, no direct association between PEBP4 and lung squamous cell carcinoma (LSCC) has been reported. In the present study, a systematic review and meta-analysis was performed to examine the gene expression activity of PEBP4 in LSCC. A total of 10 out of 131 gene expression datasets from the Gene Expression Omnibus (GEO) were selected, including 574 samples (319 patients with LSCC and 255 healthy controls). Subsequently, multiple linear regression (MLR) was employed to study three potential influencing factors: Sample size, population region and study date. A literature-based pathway analysis was then conducted to examine the potential mechanisms through which PEBP4 may exert influence on LSCC. The results of a meta-analysis indicated that, in LSCC, PEBP4 exhibited significantly low expression levels (P
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Related Links:

Conclusionsɤ-glutamyl hydroxymethyl rhodamine green fluorescence is a good postoperative prognostic indicator in patients with non-small cell lung cancer.
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Anti-angiogenic therapy represents a promising strategy for non-small-cell lung cancer (NSCLC) but its application in lung squamous cell carcinoma (SQC) is limited due to the high-risk adverse effects. Accumul...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
ConclusionsAs EV expression was related to the prognosis of lung SCC patients, a broader approach using different extracellular vesicles rather than a conventional exosome ‐dependent one is needed.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Jeon H, Eo W, Shim B, Kim S, Lee S Abstract Objectives: The impact of health-related quality of life (HRQoL) on survival has been investigated in patients with various cancers. Here, we evaluated the prognostic value of HRQoL using the Functional Assessment of Cancer Therapy-General (FACT-G) in advanced non-small-cell lung cancer (NSCLC) patients treated with Korean medicine. Methods: A retrospective review of medical records and FACT-G scores of patients with advanced NSCLC who received treatment with Korean medicine was conducted. The reliability of the FACT-G was determined using Cronbach's alpha an...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
This study aimed to evaluate the relationship between single nucleotide polymorphisms (SNPs) in the Wnt pathway and the risk of bone metastasis in patients with non-small cell lung cancer (NSCLC). We collected 500 blood samples from patients with NSCLC and genotyped eight SNPs from four core genes (WNT2, AXIN1, CTNNB1 and APC) present within the WNT pathway. Moreover, we assessed the potential relationship of these genes with bone metastasis development. Our results showed that the AC/AA genotype of CTNNB1: rs1880481 was associated with a decreased risk of bone metastasis. Polymorphisms with an HR of
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
Immune checkpoint inhibitors (ICIs) are currently used as monotherapy or combination therapy in frontline and subsequent lines for metastatic lung cancer including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer (SCLC) [1 –5]. Furthermore, ICIs before or after surgery showed efficacy in patients with resectable disease, highlighting the potential of ICIs to improve outcomes in these patients and expand the use of ICIs in the neoadjuvant and adjuvant settings [6,7]. Despite higher response rates, longer duration of response, and less toxicity of ICIs compared with chemotherapy, many lung cancer pat...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionOur findings confirm pericardial effusion as a relatively frequent side effect of immunotherapy in NSCLC. Clinicians should be aware of this specific toxicity in patients with metastatic NSCLC receiving immunotherapy and refer to a cardiologist for a multidisciplinary approach.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Lung cancer is the leading cause of cancer-related deaths mainly attributable to metastasis, especially extrathoracic metastasis. This large-cohort research is aimed to explore metastatic profiles in different histological types of lung cancer, as well as to assess clinicopathological and survival significance of diverse metastatic lesions. Lung cancer cases were extracted and enrolled from the Surveillance, Epidemiology, and End Results (SEER) database. χ2-tests were conducted to make comparisons of metastatic distribution among different histological types and odds ratios were calculated to analyze co-occurrence rela...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Hou Z, Liang X, Wang X, Zhou Z, Shi G Abstract Cancer/testis antigens melanoma-associated antigen 4 (MAGE-A4) and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) are of clinical interest as biomarkers and present valuable targets for immunotherapy; however, they are poor prognostic markers in non-small cell lung cancer (NSCLC). In addition, myeloid derived suppressor cells (MDSCs) are recognized as a key element in tumor escape and progression. The aim of the present study was to investigate the diagnostic and prognostic value of MAGE-A4 and NY-ESO-1, and their association with MDSCs in NSCLC samp...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
This report has presented a case of destroyed lung in a patient with non ‐small cell lung cancer (NSCLC) who received chemoradiotherapy followed by durvalumab. Because of the sustained inflammation and abolished function of the left lung, left pneumonectomy was required. We considered that durvalumab might further accelerate the inflammatory response, which had been in troduced by fungal infection, leading to uncontrollable inflammation of the lung. AbstractA 68 ‐year‐old male patient with squamous cell carcinoma (cT4N2M0) of the left upper lobe received chemoradiotherapy followed by durvalumab, an immune checkpoint ...
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma | Study